Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total value of $1,600,000.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at approximately $7,024,960. This trade represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Price Performance

Glaukos stock opened at $161.97 on Thursday. The stock has a market capitalization of $9.51 billion, a price-to-earnings ratio of -49.38 and a beta of 0.75. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $166.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The stock’s 50 day moving average price is $136.63 and its two-hundred day moving average price is $124.40.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The company had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. During the same quarter in the previous year, the business posted ($0.24) EPS. Glaukos’s revenue for the quarter was up 49.6% compared to the same quarter last year. On average, equities analysts predict that Glaukos Corporation will post -0.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Citigroup increased their price objective on shares of Glaukos from $162.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Stifel Nicolaus raised their target price on Glaukos from $170.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, July 17th. HC Wainwright started coverage on Glaukos in a research report on Monday, July 6th. They issued a “buy” rating and a $168.00 target price for the company. Finally, Wall Street Zen downgraded Glaukos from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $155.23.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC lifted its holdings in shares of Glaukos by 460.8% in the fourth quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after purchasing an additional 49,492 shares in the last quarter. Stephens Inc. AR bought a new stake in Glaukos during the first quarter worth $363,000. Allspring Global Investments Holdings LLC grew its holdings in Glaukos by 32.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock worth $39,336,000 after buying an additional 87,781 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new stake in Glaukos in the 4th quarter valued at $6,775,000. Finally, DNB Asset Management AS raised its position in Glaukos by 11.9% in the 4th quarter. DNB Asset Management AS now owns 82,320 shares of the medical instruments supplier’s stock valued at $9,295,000 after buying an additional 8,770 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Revenue substantially exceeded expectations: Q2 2026 net sales reached a record $185.6 million, up approximately 50% year over year and well above the roughly $151 million analyst consensus. The company’s quarterly loss of $0.14 per share was also narrower than the expected $0.21–$0.28 loss and improved from $0.24 a year earlier. Glaukos Q2 earnings report
• Positive Sentiment: Full-year outlook was raised: Glaukos forecast 2026 revenue of $680 million to $700 million, versus the prior consensus estimate of approximately $630 million. The higher outlook reinforces expectations for continued demand across its glaucoma and other eye-care products. Glaukos second-quarter financial results
• Positive Sentiment: Pipeline progress supports longer-term growth: The pivotal trial of the PRESERFLO MicroShunt for treatment-resistant glaucoma has completed enrollment, an important step toward potential regulatory and commercial expansion. PRESERFLO MicroShunt trial enrollment
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with multiple buy or outperform ratings and recent price targets ranging from $150 to $175. However, UBS initiated coverage with a neutral rating and a $150 target, indicating valuation concerns after the stock’s strong run. UBS Glaukos coverage
• Negative Sentiment: Profitability and cash flow remain weak: Glaukos continues to report an operating and net loss, while operating cash flow was negative during the quarter. Continued investment and losses could limit near-term earnings upside.
• Negative Sentiment: Insider selling may weigh on sentiment: CFO Alex Thurman sold 10,000 shares for approximately $1.6 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, reducing its significance as a discretionary bearish signal, but broader recent insider activity has consisted of sales rather than purchases. Glaukos insider sale

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.